TY  - JOUR
AU  - Eichenauer, Dennis A
AU  - Bühnen, Ina
AU  - Baues, Christian
AU  - Kobe, Carsten
AU  - Kaul, Helen
AU  - Greil, Richard
AU  - Moccia, Alden
AU  - Zijlstra, Joseé M
AU  - Hertenstein, Bernd
AU  - Topp, Max S
AU  - Just, Marianne
AU  - von Tresckow, Bastian
AU  - Eich, Hans-Theodor
AU  - Fuchs, Michael
AU  - Dietlein, Markus
AU  - Hartmann, Sylvia
AU  - Engert, Andreas
AU  - Borchmann, Peter
TI  - Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
JO  - Blood
VL  - 142
IS  - 6
SN  - 0006-4971
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2023-01643
SP  - 553 - 560
PY  - 2023
AB  - The optimal first-line treatment for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) diagnosed in early stages is largely undefined. We, therefore, analyzed 100 NLPHL patients treated in the randomized HD16 (early-stage favorable; n = 85) and HD17 (early-stage unfavorable; n = 15) studies. These studies investigated the omission of consolidation radiotherapy (RT) in patients with a negative interim positron emission tomography (iPET) (ie, Deauville score <3) after chemotherapy (HD16: 2× doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD]; HD17: 2× escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP] plus 2× ABVD). Patients with NLPHL treated in the HD16 and HD17 studies had 5-year progression-free survival (PFS) rates of 90.3
KW  - Humans
KW  - Hodgkin Disease: diagnostic imaging
KW  - Hodgkin Disease: drug therapy
KW  - Bleomycin: adverse effects
KW  - Doxorubicin
KW  - Dacarbazine
KW  - Vinblastine
KW  - Antineoplastic Combined Chemotherapy Protocols: adverse effects
KW  - Cyclophosphamide
KW  - Vincristine: adverse effects
KW  - Positron-Emission Tomography: methods
KW  - Prednisone
KW  - Bleomycin (NLM Chemicals)
KW  - Doxorubicin (NLM Chemicals)
KW  - Dacarbazine (NLM Chemicals)
KW  - Vinblastine (NLM Chemicals)
KW  - Cyclophosphamide (NLM Chemicals)
KW  - Vincristine (NLM Chemicals)
KW  - Prednisone (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:37257195
DO  - DOI:10.1182/blood.2023019939
UR  - https://inrepo02.dkfz.de/record/278409
ER  -